转移猪轮状病毒VP4基因玉米植株的获得

根据GenBank中猪轮状病毒VP4基因序列设计引物,从重组克隆载体pMD18-T-VP4中PCR扩增VP4基因,将其插入到植物表达载体pCAMBIA3301中CaMV35S启动子下游,构建成高效植物表达载体pCAMBIA3301－VP4;然后利用农杆菌介导法,以玉米自交系H99茎尖来源的玉米愈伤组织为材料,将pCAMBIA3301－VP4导入其中,分化诱导获得再生苗后,对其进行PCR、Southern杂交和RT-PCR检测。结果表明,外源目的基因VP4已成功地转入玉米基因组中,并且目的基因能在转基因玉米植株中获得转录。     

Safety and immunogenicity of BPV-1 L1 virus-like particles in a dose-escalation vaccination trial in horses

Reasons for performing study: Infection with bovine papillomaviruses types 1 and 2 (BPV‐1, BPV‐2) can lead to the development of therapy‐resistant skin tumours termed sarcoids and possibly other skin diseases in equids. Although sarcoids seriously compromise the welfare of affected animals and cause considerable economic losses, no prophylactic vaccine is available to prevent this common disease. In several animal species and man, immunisation with papillomavirus‐like particles (VLP) has been shown to protect efficiently from papillomaviral infection. Hypothesis: BPV‐1 L1 VLPs may constitute a safe and highly immunogenic vaccine candidate for protection of horses against BPV‐1/‐2‐induced disease. Methods: Three groups of 4 horses each received 50, 100 or 150 µg of BPV‐1 L1 VLPs, respectively, on Days 0, 28 and 168. Three control horses received adjuvant only. Horses were monitored on a daily basis for one week after each immunisation and then in 2 week intervals. Sera were collected immediately before, 2 weeks after each vaccination and one and 2 years after the final boost and analysed by pseudovirion neutralisation assay. Results: None of the horses showed adverse reactions upon vaccination apart from mild and transient swelling in 2 individuals. Irrespective of the VLP dose, all VLP‐immunised horses had developed a BPV‐1‐neutralising antibody titre of ≥1600 plaque forming units (pfu)/ml 2 weeks after the third vaccination. Eight of 10 trial horses still available for follow‐up had neutralising antibody titres ≥1600 pfu/ml one year and ≥800 pfu/ml 2 years after the last immunisation. Conclusion: Intramuscular BPV‐1 L1 VLP vaccination in horses is safe and results in a long‐lasting antibody response against BPV‐1. Neutralisation titres were induced at levels that correlate with protection in experimental animals and man. Potential relevance: BPV‐1 L1 VLPs constitute a promising vaccine candidate for prevention of BPV‐1/‐2‐induced disease in equids.     

自家苗治疗连城白鸭浆膜炎的效果研究

选择刚死亡且具有典型鸭传染性浆膜炎病变的病死鸭,无菌采集其肝组织,对疑似鸭疫里默氏杆菌进行分离鉴定,证明确为鸭疫里默氏杆菌,然后将该菌株扩增培养,通过甲醛灭活,再经无菌试验和安全性试验验证,制成安全的自家苗,随后对自家苗作临床效力试验,结果证明该苗具有较好的免疫防治效果,适合在当地推广使用。     

口服疫苗抗原递送载体Lactococcus lactis NZ9000研究进展

综述了基因工程菌Lactococcus lactis NZ9000在基因组学、安全性、功能性、疫苗载体构建、菌株改造等方面的研究进展,对NZ9000作为口服疫苗载体的表达系统进行了评述,展望了其在生物制药、疫苗开发和食品工业等领域的应用前景,并对今后研究的发展方向做了分析。     

猪流感H1N1亚型病毒dM2蛋白的原核表达及鉴定

为构建猪流感病毒H1N1亚型dM2蛋白的原核表达系统,获得具有生物活性的GST—dM2重组蛋白。研究从H1N1亚型猪流感病毒核酸中克隆出M2全长基因,采用OE—PCR技术得到缺失跨膜区的M2基因（dM2）,构建重组表达质粒pGEX-6p—dM2,转化大肠杆菌BL21,经IPTG诱导表达后,进行GST亲和层析柱纯化和Western—blotting鉴定。结果表明GST—dM2融合蛋白在大肠杆菌BL21中获得较高表达,并以可溶形式存在,表达量为22．75％。纯化后的GST—dM2重组蛋白为38kD,经Western—blotting证明具有良好的反应原性。GST—dM2重组蛋白的成功获得,为拼-步研密猪流感哑单位癌苗奠定了某础．     

胸膜肺炎放线杆菌apxIIC-/kanr 基因缺失减毒株的构建

重组转移载体pBSKA通过电转化导入亲本菌胸膜肺炎放线杆菌血清7型（APP-7）WF83株,电转化后的产物涂布于TSB／Kan平板,2d获得突变株。卡那霉素抗性实验证实突变株有卡那霉素抗性;NAD依赖性实验证实突变株依赖NAD生长;PCR鉴定证实了卡那霉素抗性基因置换了apxlIC基因,并证实突变株中无pBSKA质粒的存在;溶血活性实验证实突变株完全失去了溶血活性;细胞毒性实验证实突变株的细胞毒性完全丧失;对小鼠的安全性实验证实突变株的毒力显著减弱,突变株对小鼠是安全的;遗传稳定性实验证实,突变株在体外连续传30代和在体内传10代均不会发生卡那霉素抗性的丢失。结果表明实验成功构建了基因缺失减毒株,为进一步以此突变株作为基因工程弱毒活疫苗株开展研究奠定了一定的基础。     

鸡球虫重组活载体疫苗研究进展

对细菌和病毒为载体的鸡球虫重组活载体疫苗研究进行了综述,旨在为鸡球虫病的免疫预防提供新思路和参考.     

反应器细胞悬浮培养和微载体培养技术在动物疫苗生产中的应用

介绍了反应器悬浮培养技术在国内外疫苗生产中的研发和应用现状。目前该技术已经在国内口蹄疫疫苗生产中获得成功应用,利用MDCK、Vero等细胞培养生产禽流感疫苗的技术也正在积极研发中。积极推广和应用这一技术将是我国兽用生物制品生产工艺升级换代的必然趋势。     

禽流感病毒通用型及H5亚型套式荧光RT-PCR 检测方法研究

将套式PCR与荧光RT-PCR技术相结合,叠加这两种技术在敏感性和特异性方面的优势,建立敏感性高于常规荧光RT-PCR的套式荧光RT-PCR检测方法。从GenBank下载禽流感病毒NP基因和HA基因序列,通过比对选取较为保守的片段,设计AIV通用型及H5亚型套式荧光RT-PCR引物和TaqMan探针;利用体外转录技术制备阳性对照,构建目的片段重组质粒;经反应体系和反应条件的优化,建立套式荧光RT-PCR检测方法。试验结果表明,该方法可特异性地检测禽流感病毒及H5亚型AIV,在30份鱼类养殖水样中检测到19份阳性样品,具有较高的敏感性和良好的特异性;具有高通量、快速的特点,可对大批量样品同时进行检测,试验耗时仅需5 h,是自然环境样品中极微量禽流感病毒检测的好方法。